Xconomy | Boston - Business + Technology in the Exponential Economy

Ironwood Nabs $75M in Deal With Japanese Firm, Gloucester Drug Gets FDA Approval, Alnylam Branches Into Biomanufacturing Tech, & More Boston-Area Life Sciences News
Oral RNAi Drug Stops Inflammation in Mice, RXi Says
Oral Pill May Make Tough-to-Deliver RNAi Drugs Go Down Easy, RXi Says
RXi Takes a Untraditional Route to the Public Market, Now Working To Get Pharma to Pay The Bills
Alnylam, RXi On Collision Course Over Intellectual Property From Massachusetts Life Sciences Initiative

Biotech, people, RNA Interference

RXi Replaces CEO

Luke Timmerman 11/6/09

RXi Pharmaceuticals (NASDAQ: RXII), the Worcester, MA-based developer of RNA interference drugs, said today that Noah Beerman has replaced Tod Woolf as president and CEO. Beerman, 47, was most recently chief business officer of Indevus Pharmaceuticals. The company said the leadership switch was part of a succession plan as it looks to advance into product development. Woolf will remain on the company’s scientific advisory board.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: